Seongnam-si, South Korea

Sha Joung Chang

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.4

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Sha Joung Chang

Introduction

Sha Joung Chang is a notable inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neural damage and cancer. With a total of 2 patents, his work focuses on developing compounds that can improve cognitive functions and combat degenerative diseases.

Latest Patents

Chang's latest patents include a compound and pharmaceutical composition aimed at treating or preventing neural damage, neural diseases, or developmental disorders. This invention promotes the proliferation, differentiation, and regeneration of neural cells. The compound may serve as a therapeutic agent for degenerative brain diseases, including dementia, and various neural damage diseases. Additionally, it acts as a learning ability-improving agent and a cognitive function-enhancing agent. Another significant patent involves a compound with a novel structure, which is part of an anti-cancer pharmaceutical composition and drug. This compound is designed to combat cancer effectively.

Career Highlights

Throughout his career, Chang has worked with various organizations, including Etnova Therapeutics Corporation and Kyungpook National University Industry-Academic Cooperation Foundation. His experience in these institutions has allowed him to collaborate on groundbreaking research and development projects.

Collaborations

Chang has collaborated with notable coworkers such as Yong Min Chang and Yeoun Hee Kim. Their joint efforts have contributed to the advancement of innovative solutions in the pharmaceutical industry.

Conclusion

Sha Joung Chang's contributions to the field of pharmaceuticals highlight his dedication to improving health outcomes through innovative inventions. His work continues to pave the way for advancements in treating neural and cancer-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…